SEC Form 4 · accession 0001213900-26-064792
Protara Therapeutics, Inc. · TARA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Conkling
Officer — Chief Commercial Officer
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 4:55 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001359931
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 2, 2026 | F | 6,008 | $4.34 | D | 69,992 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F11. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on June 2, 2025.